Clinical Trials Logo

Filter by:
NCT ID: NCT02579148 Withdrawn - Clinical trials for Type 2 Diabetes Mellitus

Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes

Start date: September 2015
Phase: Phase 1
Study type: Interventional

The intent of this clinical study is to answer the questions: 1) is the proposed treatment feasible; 2) is treatment effective in improving the disease pathology of patients with diagnosed diabetic erectile dysfunction.

NCT ID: NCT02575261 Withdrawn - Clinical trials for CAR-T Cell Immunotherapy

CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients

Start date: September 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in treating with EphA2 positive malignant glioma patients.

NCT ID: NCT02551003 Withdrawn - Cerebral Infarction Clinical Trials

Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy

Start date: September 8, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This study examines the effect of cord blood in the treatment of newborn infants with neonatal encephalopathy in combination with hypothermia, which is the standard treatment for this condition. The hypothesis is that the cord blood + hypothermia combination will produce better neuroprotection than the standard treatment of hypothermia alone.

NCT ID: NCT02547961 Withdrawn - Breast Cancer Clinical Trials

Chimeric Antigen Receptor-Modified T Cells for Breast Cancer

Start date: September 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of HER2-CAR-T cell Infusion for advanced HER2 positive breast cancer.

NCT ID: NCT02547948 Withdrawn - B Cell Lymphoma Clinical Trials

CD19-targeting CAR T Cells for B Cell Lymphoma

Start date: September 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of CD19-targeting CAR T Cells infusion for B Cell Lymphoma.

NCT ID: NCT02539017 Withdrawn - Clinical trials for Triple Negative Breast Neoplasms

The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer

Start date: November 2015
Phase: Phase 2
Study type: Interventional

As a special type of breast cancer, the triple negative breast cancer has the characteristics of high recurrence rate (2 years after surgery), high distant metastasis rate, poor prognosis and short survival time. No matter at home or abroad, the clinical researches of the triple negative breast cancer are mainly focused on finding new drugs and new treatment strategies in order to reduce its recurrence and distant metastasis rate. The DC/CIK cell immunotherapy combined with chemotherapy in the clinical study of metastatic triple negative breast cancer has already confirmed benefit. This study is based on the theory that the optimal timing of cellular immunity is while the host tumor load is under the smallest state. Put forward the hypothesis that the DC/CIK cell immunotherapy combined with chemotherapy may improve the disease-free survival and overall surviva after the triple negative breast cancer operation. The investigators intends to use the RCT, observing the clinical significance of cellular immune adjuvant therapy of triple negative breast cancer in 340 patients with TNBC. Do the safety evaluation of cellular immunity in the adjuvant treatment of breast cancer treatment, explore the clinical strategies for breast cancer immunotherapy.

NCT ID: NCT02487316 Withdrawn - Clinical trials for Systemic Anaplastic Large-Cell Lymphoma

A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib

Start date: July 2015
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of crizotinib combined with CHOP chemotherapy for patients with ALK(+) Systemic Anaplastic Large Cell Lymphoma.

NCT ID: NCT02449967 Withdrawn - Pancreatic Cancer Clinical Trials

HepaSphere Interventional Therapy Using Digital Subtraction Angiography(DSA) for Pancreatic Cancer

Start date: May 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction Angiography(DSA)for pancreatic cancer.

NCT ID: NCT02430649 Withdrawn - Prostatic Neoplasms Clinical Trials

Irreversible Electroporation(IRE) For Unresectable Prostatic Neoplasms

IRE
Start date: January 1, 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of irreversible electroporation (IRE) for unresectable Prostatic Neoplasms.

NCT ID: NCT02398318 Withdrawn - Clinical trials for Obsessive Compulsive Disorder

China Refractory Obsessive-Compulsive Disorder Deep Brain Stimulation Study

CRODS
Start date: April 2015
Phase: Phase 2/Phase 3
Study type: Interventional

Refractory obsessive-compulsive disorder (OCD) is a disabling condition. Deep brain stimulation (DBS) of the nucleus accumbens is the most tested therapeutic avenue for refractory OCD. However, large scale randomized controlled trials to evaluate the effectiveness of this approach are rare.